NCT03618472View on ClinicalTrials.gov

Comparison of the Effectiveness Metformin for Deceasing Proliferative Marker in Endometrial Cancer Cells

NACompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

July 1, 2018

Primary Completion Date

November 30, 2019

Study Completion Date

January 30, 2020

Conditions
MetforminCA Endometrium
Interventions
DRUG

Metformin Hydrochloride 850 MG

Regular strength metformin (850 mg/tab)

DRUG

Placebo Oral Tablet

Starch based placebo manufatured to mimic Metformin 850 mg

Trial Locations (1)

10400

Rajavithi Hospital, Bangkok

All Listed Sponsors
lead

Department of Medical Services Ministry of Public Health of Thailand

OTHER_GOV

NCT03618472 - Comparison of the Effectiveness Metformin for Deceasing Proliferative Marker in Endometrial Cancer Cells | Biotech Hunter | Biotech Hunter